 |
 |
|
 |
| 「寄付講座 臨床遺伝学研究室」の研究業績のデータです。 |
|
[ 論 文 ]
| 1. |
Shiga T., Tsukimura T., Kubota T., Togawa T., Sakuraba H.: Profiles of globotriaosylsphingosine analogues and globotriaosylceramide isoforms accumulated in body fluids from various phenotypic Fabry patients. Intern Med., 63: 1531-1537, 2024.
|
| 2. |
Shima H., Tsukimura T., Shiga T., Togawa T., Sakuraba H., Doi T., Ikeda Y., Okamoto T., Yoshikawa Y., Kimura T., Iwase T., Inoue T., Tashiro M., Oakada K., Minakuchi J.: Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report. CEN Case Rep., 13: 290-296, 2024.
|
| 3. |
Tsukimura T., Saito K., Shiga T., Ogawa Y., Sakuraba H., Togawa T.: Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice? Mol. Genet. Metab. Rep., 39:101079, 2024.
|
| 4. |
Hotta J., Jogu Y., Bamba H., Izumiya Y., Kudo M., Imai T., Sakuraba H., Hamazaki T., Seto T.: Potential usefulness of lifetime globotriaosylsphingosine exposure at diagnosis and baseline modified disease severity score in early-diagnosed patients with Fabry disease. Cureus, 16: e61380, 2024.
|
| 5. |
Tsukimura T., Shiga T., Togawa T., Sakuraba H.: Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice. Mol. Genet. Metab. Rep., 40: 101118, 2024.
|
 |
|
|
|
|
|
|
|
|
| |
